# Emerging therapies targeting lipoprotein(a): the next frontier in cardiovascular risk reduction

## TL;DR

This paper reviews new therapies targeting lipoprotein(a) to reduce cardiovascular risk, focusing on RNA-based and small-molecule drugs that significantly lower Lp(a) levels.

## Contribution

The paper provides an overview of emerging RNA-based and small-molecule therapies that effectively reduce Lp(a) levels and their potential to redefine cardiovascular risk management.

## Key findings

- RNA-based therapies like antisense oligonucleotides and small-interfering RNAs reduce Lp(a) levels by 80–90%.
- Early evidence suggests these therapies may lower oxidized phospholipids and vascular inflammation.
- Large outcome trials are ongoing to assess cardiovascular and valvular benefits of Lp(a)-lowering therapies.

## Abstract

Lipoprotein(a) [Lp(a)] is a genetically determined lipoprotein particle composed of apolipoprotein B-100 covalently linked to apolipoprotein(a) [apo(a)] via a disulfide bond. The Lp(a) particle is enriched with oxidized phospholipids (OxPLs), which confer enhanced atherogenic and pro-inflammatory properties compared with low-density lipoprotein (LDL). Robust genetic and epidemiologic evidence demonstrates that elevated Lp(a) levels are independently associated with atherosclerotic cardiovascular disease and calcific aortic valve stenosis. However, no pharmacologic therapy has yet been approved that specifically lower Lp(a) or to demonstrate a reduction in cardiovascular events. Antisense oligonucleotides (e.g., pelacarsen), small-interfering RNAs (e.g., olpasiran, lepodisiran, and zerlasiran), and oral small-molecule Lp(a) inhibitors (e.g., muvalaplin) have demonstrated profound reductions in circulating Lp(a) concentrations, typically achieving decreases of 80–90%. In some studies, the reductions approached or achieved a near-complete suppression. Current genetic and modeling evidence suggests that an absolute reduction of at least 50 mg/dL in Lp(a) levels is required to achieve meaningful cardiovascular benefits. Large-scale outcome trials are now underway to assess the effects of these emerging therapies on cardiovascular and valvular outcomes. Early findings indicate favorable effects on oxidized phospholipids and vascular inflammation, suggesting broader anti-atherogenic potential. As these agents progress toward clinical use, routine Lp(a) measurement and risk stratification will become increasingly essential for personalized cardiovascular prevention. This review summarizes the molecular biology of Lp(a), highlights the limitations of current therapies, and discusses emerging RNA-based and small-molecule approaches with the potential to redefine the management of residual cardiovascular risk.